Ascendis Pharma A (ASND) Equity Income (2019 - 2026)
Ascendis Pharma A (ASND) posted Equity Income of -$12.0 million for Q1 2026, down 876.36% sequentially from $1.5 million in Q4 2025, and down 142.93% YoY from $28.0 million in Q1 2025.
Ascendis Pharma A (ASND) Equity Income (2019 - 2026) Analysis & Trends
Ascendis Pharma A has reported Equity Income for 8 years, with the latest figure at -$12.0 million in Q1 2026.
- Quarterly Equity Income fell 142.93% year-over-year to -$12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.9 million (down 290.26% YoY) and the FY2025 annual result came in at $19.0 million, up 188.56% from the prior year.
- Equity Income slipped to -$12.0 million in Q1 2026 per ASND's latest filing, from $1.5 million in the prior quarter.
- Over five years, Equity Income peaked at $28.0 million in Q1 2025 and troughed at -$12.0 million in Q1 2026.
- A 5-year average of -$2.7 million and a median of -$4.8 million in 2024 frame the typical range for Equity Income.
- The sharpest annual moves came in 2023 and 2025: Equity Income sank 552.12% in 2023, then surged 544.02% in 2025.
- Over 5 years, Equity Income stood at -$8.1 million in 2022, then soared by 61.27% to -$3.1 million in 2023, then slumped by 55.4% to -$4.9 million in 2024, then jumped by 131.62% to $1.5 million in 2025, then sank by 876.36% to -$12.0 million in 2026.
- According to Business Quant data, Equity Income over the past three periods registered -$12.0 million, $1.5 million, and -$8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.00 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | -8.77 Mn |
| Jun 30, 2025 | -4.64 Mn |
| Mar 31, 2025 | 27.96 Mn |
| Dec 31, 2024 | -4.89 Mn |
| Sep 30, 2024 | -4.80 Mn |
| Jun 30, 2024 | -5.73 Mn |
| Mar 31, 2024 | -6.30 Mn |
| Dec 31, 2023 | -3.15 Mn |
| Sep 30, 2023 | -7.40 Mn |
| Jun 30, 2023 | -8.11 Mn |
| Mar 31, 2023 | -1.32 Mn |
| Dec 31, 2022 | -8.12 Mn |
| Sep 30, 2022 | -3.73 Mn |
| Jun 30, 2022 | -1.24 Mn |
| Mar 31, 2022 | 5.47 Mn |
| Dec 31, 2021 | -8.46 Mn |
| Sep 30, 2021 | -4.55 Mn |
| Jun 30, 2021 | -5.80 Mn |